GHK sequence raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-11-07 and is reviewed periodically as new material appears.
The peptide portion consists of three amino acids: glycine, histidine and lysine. Copper(II) coordinates through the imidazole nitrogen of histidine, the alpha-amino group of glycine and a deprotonated amide nitrogen of the backbone, producing a roughly square-planar geometry. This arrangement gives the complex its characteristic blue-to-violet colour and helps it resist dissociation in water. Reported stability constants are high, although values differ between studies because of differences in ionic strength and measurement method.
The International Nomenclature of Cosmetic Ingredients lists the substance as copper tripeptide-1, the name that appears on most topical product labels. Related designations include copper peptide and GHK-Cu, and the hyphenated form is common in research literature. In cosmetics the material is regulated as an ingredient rather than as a drug, so products may reach the market without evidence of the effects claimed for them. Whether those effects are clinically meaningful is an open question, since most supportive data come from laboratory work and small trials.
Aqueous solutions of GHK-Cu are less stable than the dry powder. The peptide backbone is vulnerable to hydrolysis at extreme pH, and copper can be stripped from the complex by strong chelating agents such as EDTA or citrate. Oxidising agents and high concentrations of ascorbic acid can reduce copper(II) and change the complex, which is one reason formulators often keep such ingredients in separate phases. How quickly these changes occur under real storage conditions depends on pH, buffer, temperature and packaging, and quantitative data on the subject are limited.
Dry material is normally held cold, commonly at -20 °C for long-term storage and 2 to 8 °C for working quantities, protected from light and moisture. Vials should be allowed to reach room temperature before opening so that condensation does not form on the powder. In liquid formulations the complex is generally kept near neutral to slightly acidic pH, because strongly alkaline conditions favour precipitation of copper hydroxide. Antioxidants or chelate-stabilising excipients are often added, though the specific approaches are proprietary and rarely published in detail.
| Property | Value | Notes |
|---|---|---|
| INCI name | Copper tripeptide-1 | Standard designation on cosmetic ingredient labels |
| Peptide sequence | Gly-His-Lys | Three-residue ligand; binding occurs at the histidine side chain |
| Metal-to-peptide ratio | 1 to 1 | One copper(II) ion per peptide unit |
| Appearance | Blue to violet powder | Colour arises from copper-to-peptide electronic transitions |
| Water solubility | Freely soluble | Commonly formulated in aqueous or water-alcohol systems |
The copper-binding activity of this sequence was described in the 1970s during studies of liver tissue and plasma factors. Early work identified the peptide as a component that influenced copper uptake by cells and that appeared in wound fluid. Later investigations examined its presence across species, reporting the same chain in human and animal samples. A decline in measured concentration with age became a recurring observation, although the underlying causes remain incompletely characterised.
Published studies describe the complex in several research contexts, including collagen synthesis, antioxidant behaviour, and wound repair models. Much of this work is conducted in cultured cells or in small animal systems, and the findings are frequently cited in reviews of copper peptides. Direct clinical evidence in humans is comparatively limited, and reported outcomes vary with formulation and study design. Whether free chain or metal-bound form was used is not always stated, a point that complicates comparison between reports.
GHK-Cu is a coordination complex formed between the peptide glycyl-L-histidyl-L-lysine and a copper(II) ion. The unbound chain, abbreviated GHK, consists of three amino acids and occurs naturally in human plasma, saliva, and urine. Binding of the metal is mediated mainly by the imidazole nitrogen of the histidine residue together with backbone amides, producing a stable chelate. Ingredient nomenclature often lists the same substance as copper tripeptide-1. Its charge and solubility behaviour differ from those of the metal-free chain.
Analytical verification commonly relies on high-performance liquid chromatography for purity assessment and mass spectrometry for identity confirmation. Spectroscopic methods such as UV-visible absorption and electron paramagnetic resonance can probe the metal centre itself, since the d9 configuration of copper(II) produces characteristic signals. Elemental analysis or plasma-based techniques quantify copper content. Because each method reports a different aspect of the same sample, purity figures are most meaningful when the technique and its detection wavelength are stated alongside the value.
Stability of the complex in solution depends on pH, temperature, and the presence of competing ligands. It is generally described as more resistant to breakdown than the metal-free chain, since coordination reduces susceptibility to enzymatic attack. Oxidation and hydrolysis can nevertheless proceed over time in aqueous media. Storage guidance in laboratory settings commonly involves refrigeration, protection from light, and avoidance of strongly alkaline conditions. Published data on long-term behaviour vary considerably and depend on the specific matrix.
Handling practices for the solid material emphasise low temperature and dryness. The lyophilised or powdered form is typically kept at refrigerator or freezer temperatures together with a desiccant. Working solutions are often prepared fresh, because repeated freeze-thaw cycles and extended storage may alter the complex. Glass or inert plastic containers are preferred over materials that could leach metal ions into the preparation. Such practices follow general peptide conventions rather than substance-specific regulations.
Copper(II) binds the peptide through four nitrogen donors: the terminal amino group, the imidazole nitrogen of histidine, and two deprotonated amide nitrogens of the peptide backbone. This tetradentate arrangement gives a roughly square-planar geometry, the thermodynamically favoured form near neutral pH. Because the amide nitrogens must lose a proton before they can coordinate, complex formation is strongly pH-dependent, and the fully coordinated species dominates only above mildly acidic conditions. Electronic transitions within the copper d orbital set produce the characteristic blue to violet colour in aqueous solution.
Endogenous GHK occurs in blood plasma, saliva, and urine, and reported plasma concentrations decline with age in several studies. Researchers have proposed that the peptide acts as a copper carrier that delivers the metal to cells and to sites of injury. That transport role is a hypothesis supported by binding measurements and tissue-distribution data rather than a settled mechanism, and the peptide is generally described as a minor contributor to total plasma copper transport. Values reported in wound fluid and certain tissue extracts are higher than in circulating plasma.
=== Injury and workload === Fractures to bones during or after excavation appear relatively fresh, with broken surfaces appearing white and unweathered. Distinguishing between fractures around the time of death and post-depositional fractures in bone is difficult, as both types of fractures show signs of weathering. Unless evidence of bone healing or other factors are present, researchers may choose to regard all weathered fractures as post-depositional. Evidence of perimortal fractures (or fractures inflicted on a fresh corpse) can be distinguished in unhealed metal blade injuries to the bones. Living or freshly dead bones are somewhat resilient, so metal blade injuries to bone generate a linear cut with relatively clean edges rather than irregular shattering. Archaeologists have attempted to use the microscopic parallel scratch marks on cut bones in order to estimate the trajectory of the blade that caused the injury.
=== Transitional phases === Transitional phases at the onset or departure of El Niño or La Niña can also be important factors on global weather by affecting teleconnections. Significant episodes, known as Trans-Niño, are measured by the Trans-Niño index (TNI). Examples of affected short-time climate in North America include precipitation in the Northwest US and intense tornado activity in the contiguous US.
Uranium–lead radiometric dating involves using uranium-235 or uranium-238 to date a substance's absolute age. This scheme has been refined to the point that the error margin in dates of rocks can be as low as less than two million years in two-and-a-half billion years. An error margin of 2–5% has been achieved on younger Mesozoic rocks. Uranium–lead dating is often performed on the mineral zircon (ZrSiO4), though it can be used on other materials, such as baddeleyite and monazite (see: monazite geochronology). Zircon and baddeleyite incorporate uranium atoms into their crystalline structure as substitutes for zirconium, but strongly reject lead. Zircon has a very high closure temperature, is resistant to mechanical weathering and is very chemically inert. Zircon also forms multiple crystal layers during metamorphic events, which each may record an isotopic age of the event. In situ micro-beam analysis can be achieved via laser ICP-MS or SIMS techniques. One of its great advantages is that any sample provides two clocks, one based on uranium-235's decay to lead-207 with a half-life of about 700 million years, and one based on uranium-238's decay to lead-206 with a half-life of about 4.5 billion years, providing a built-in crosscheck that allows accurate determination of the age of the sample even if some of the lead has been lost. This can be seen in the concordia diagram, where the samples plot along an errorchron (straight line) which intersects the concordia curve at the age of the sample.
Sources: en.wikipedia.org
=== Tuberculosis === The primary use of isoniazid is as first-line treatment for latent and active infection of Mycobacterium tuberculosis, the causative agent of tuberculosis (TB). In persons with isoniazid-resistant Mycobacterium tuberculosis infection, drug regimens based on isoniazid have a high rate of failure. In the United States, the indications for isoniazid use approved by the U.S. Food and Drug Administration (FDA) include:.
Neuropeptide FF group Neuropeptide AF Neuropeptide FF Neuropeptide SF (RFRP-1) Neuropeptide VF (RFRP-3) (GnIH - avian species) Prolactin-releasing peptide (PrRP) Pyroglutamylated RFamide peptide (QRFP) Kisspeptin (disputed)
In a TV interview in February 2001, Bush's new attorney general, John Ashcroft, said about the war on drugs, "I want to renew it. I want to refresh it, relaunch it if you will." In 2001, after 9/11 and the Patriot Act, the DEA began highlighting the tie between drug trafficking and international terrorism, gaining the agency expanded funding to increase its global presence.
=== Cost === GLP-1 agonists are more expensive than other treatments for type 2 diabetes. A study compared the cost-effectiveness of GLP-1 agonists to long-acting insulin in a Taiwanese population with type 2 diabetes. In people with cardiovascular disease (CVD), GLP-1 agonists were estimated to save money due to fewer cardiovascular incidents. In people without CVD, the cost per QALY was $9,093. In the United States, cost is the highest barrier to GLP-1 agonist usage and was reported as the reason for discontinuation in 48.6% of people who stopped using the drugs. According to a 2023 study, GLP-1 agonists were not cost-effective for pediatric obesity in the U.S. As of late 2025, prices had dropped substantially. In 2025 it was estimated that Medicare coverage of GLP-1RA agonists for obesity in the United States would increase federal spending by $69.5 billion over a decade. Mixed results have been found when economic evaluations of glucagon like peptide-1 (GLP-1) receptor agonists have been done, specifically in response to its use for obesity treatment in people without diabetes. A 2026 review concluded that, due to their high acquisition costs, GLP-1 receptor agonists are generally not cost-effective compared to lifestyle interventions or no treatment at all from a healthcare-payer perspective. The analysis also reported that cost-effectiveness outcomes vary drastically depending on assumptions related to treatment duration, long-term weight maintenance, and the time horizon of the specific model.
Sources: en.wikipedia.org
It is a complex of a three-amino-acid peptide, glycine, histidine and lysine, bound to a single copper(II) ion. The metal is held mainly by the histidine side chain and the peptide backbone. Most commercial material is supplied as an acetate salt rather than as the free complex.
The free peptide was reported in 1973 by Loren Pickart, who isolated it from human plasma. Its copper-binding behaviour was characterised over the following years. The metal-bound form has been the subject of most later research.
Yes. Copper tripeptide-1 is the name used in cosmetic ingredient labelling, while GHK-Cu is the shorthand found in the scientific literature. Both refer to the same peptide-copper complex, and the two terms are interchangeable in most technical documents.
Dry powder is best kept cold, dark and sealed, typically at -20 °C for long-term storage or 2 to 8 °C for material in regular use. Vials should be warmed to room temperature before opening to prevent moisture condensing on the contents. Aqueous stock solutions degrade faster and are usually prepared fresh.